Skip to main content
Erschienen in: BMC Infectious Diseases 1/2019

Open Access 01.12.2019 | Research article

CD40 polymorphisms were associated with HCV infection susceptibility among Chinese population

verfasst von: Ting Tian, Peng Huang, Jingjing Wu, Chunhui Wang, Haozhi Fan, Yun Zhang, Rongbin Yu, Chao Wu, Xueshan Xia, Zuqiang Fu, Jun Li, Ming Yue

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2019

Abstract

Background

CD40, encoded by TNFRSF5, participates in the survival of B cells, process of antigen presentation and generation of CD8+ T cell memory. It also has an important effect on HCV antiviral immune response. This study aims to investigate whether TNFRSF5 gene polymorphisms are associated with HCV infection outcomes among Chinese population.

Methods

Three single nucleotide polymorphism (SNPs) (rs1535045, rs1883832, rs4810485) on TNFRSF5 were genotyped by TaqMan assay among Chinese population, including 1513 uninfected subjects, 496 spontaneous viral clearance subjects and 768 persistent HCV-infected subjects. Logistic analysis was used to compare these SNPs among different groups in this cross-sectional study. Functional annotations of the identified SNPs were further evaluated by bioinformatics analysis.

Results

After adjusted by age, gender and routes of infection, the results of logistic analysis indicated that individuals carrying rs1535045 T allele had a higher risk to infect HCV compared with C allele (in recessive model, adjusted OR = 1.368, 95%CI = 1.070-1.749, P = 0.012). Subjects carried rs1535045 TT genotype were more likely to infect HCV than wild CC genotype (adjusted OR = 1.397, 95%CI = 1.078-1.809, P = 0.011). For rs1883832, T allele was significantly associated with an increased risk of HCV infection (in recessive model, adjusted OR = 1.337, 95%CI = 1.069-1.673, P = 0.011). Subjects with TT genotype had more possibility to infect HCV (adjusted OR = 1.351, 95%CI = 1.060-1.702, P = 0.015). In the stratified analysis, rs1535045 and rs1883832 were remained in various subgroups and the heterogeneity test showed no pronounced heterogeneity in any pairwise comparison (all P > 0.05). In addition, the results of the cumulative effects showed a tendency of that the more risk alleles (rs1535045 T and rs1883832 T) subjects carried, the more possibility of HCV infection exhibited (P<0.001). In haplotype analyses, compared with the CC haplotype, CT, TC and TT was correlated with an increased risk to infect HCV (P = 0.029, P = 0.047 and P<0.001, respectively).

Conclusions

In conclusion, CD40 polymorphisms were significantly associated with the susceptibility to HCV among Chinese populations.
Hinweise
Ting Tian and Peng Huang contributed equally to this work.

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12879-019-4482-5.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
ALT
Alanine transaminase
AST
Aspartate aminotransferase
DAAs
Direct acting antivirals
eQTL
Expression Quantitative Trait Loci
HCV
Hepatitis C virus
LD
Linkage disequilibrium
MAF
Minor allele frequency
TNFRSF5
Tumor necrosis factor receptor superfamily 5

Background

It is estimated that more than 184 million people around the world are infected with hepatitis C virus (HCV). HCV infection has brought about large burden on many countries resulting from the highly correlated hepatic and extrahepatic disorders such as cirrhosis, hepatocellular carcinoma and hepatic failure [1]. Furthermore, current vaccines are not available for effective prevention of HCV infection [2].
As is known, host genetic factors play an important role in infection outcome of HCV and the response to antiviral therapies [3]. IL-28B rs12979860 and HLA class II rs4273729 are independently associated with spontaneous resolution of HCV infection [4]. Genome-wide association studies (GWASs) of patients with chronic hepatitis C have identified the association between IL28B variations, especially rs12979860 and rs8099917, and response to treatment with peg–interferon alpha and ribavirin [5, 6]. Therefore, it is still essential to figure out the atlas of disease related genetic factors.
CD40, also known as tumor necrosis factor receptor superfamily 5 (TNFRSF5), which is principally expressed on the B cells, participates in the survival of B cells, process of antigen presentation and generation of CD8+ T cell memory [7]. It also has an important effect on antiviral immune response. In HCV-associated chronic liver diseases, CD40 is highly expressed on liver tissues and has a key role in hepatocyte survival [8]. To be more specific, CD40 can inhibit HCV replication and mediate viral clearance, and disruptions by activated innate immune mechanism [9]. CD40 gene polymorphisms have been found to be associated with many immune related disorders, for instance, Kawasaki Disease, systemic lupus erythematosus and lung cancer [1012]. According to previous study, rs1535045 T allele was higher than C allele in Coronary Artery Disease (CAD) patients [12]. It also has been found that rs1883832 T allele was associated with higher risk of sepsis [13]. One meta-analysis showed a significant association between the CD40 rs4810485 T allele and rheumatoid arthritis (RA) [14] However, so far, no relevant research has addressed the association between CD40 genetic variants and HCV infection susceptibility or outcomes. Hence, this study aimed to explore the relationships between CD40 genetic variants and HCV infection outcomes among a Chinese high-risk population, including rs1535045, rs1883832 and rs4810485.

Methods

Study subjects

This study incorporates three high risk populations up to 2777 subjects. We recruited 720 hemodialysis (HD) subjects from nine hospital hemodialysis centers from October 2008 to May 2015, 459 intravenous drug users recruited from Nanjing compulsory detoxification center from December 2008 to November 2012 and 1598 paid blood donors from six villages in Zhenjiang City from October 2008 to September 2016. Exclusion criteria are as follows: 1. concurrently infected with other virus (human immunodeficiency virus or hepatitis B virus); 2. suffered from any other liver diseases (e.g. alcoholic, autoimmune or metabolic liver diseases); 3. accepted any antiviral therapies during this whole study. All participants were categorized into three groups. Group A were health subjects who were tested both anti-HCV and HCV-RNA negative. Group B were the spontaneous clearance group who were tested anti-HCV positive and HCV-RNA negative. Group C were called persistent infection group whose anti-HCV and HCV RNA were both seropositive. It is worth noting that all serological results were verified by three independent experiments within six consecutive months.
Demographic data, dangerous behavior exposure and medical histories of HCV infection were collected through structured questionnaires designed by professionals. Only achieved the rigorous professional trainings could the investigators carry out the interview for each participant. Quality control was throughout the entire process of investigation in order to make sure that the collected data was true and reliable.

Viral testing

After the interview, an approximately 10-mL morning fasting venous blood was collected from each participant. The serum and white blood cells were isolated at the speed of 4000 rpm for 10 min immediately and refrigerate at − 80 °C before using. Taking appropriate approaches for detection of anti-HCV antibodies, HCV-RNA and diverse HCV genotypes followed by the standard operating protocols. The reagents used for each step were the third-generation enzyme-linked immunosorbent assay (for anti-HCV antibody), Trizol LS Reagent (for HCV-RNA) and Murex HCV Serotyping 1–6 Assay ELISA kit (for HCV genotype).

SNPs selection and genotyping

SNP searching strategies: 1) Candidate TNFRSF5 tagSNPs were download on the 1000 Genomes Project SNP database (www.​internationalgen​ome.​org) and selected through Haploview 4.2 software, 2) Potential functional SNPs predicted by following databases (UCSC, HaploReg v4.1, GTEx Portal, SNP Function Prediction, and microRNA-related SNP), 3) Relevant SNPs discovered by others scholars associated with viral hepatitis or other liver and immune-related disorders, 4) According to the criteria, the minor allele frequency (MAF) of selected SNPs must be more than 5% among Chinese Han population. Finally, three SNPs (rs1535045, rs1883832 and rs4810485) were chosen into this study.
Genomic DNA of each subject was extracted from peripheral blood leukocytes by proteinase K and phenol-chloroform respectively, and further purified by ethanol precipitation. We used TaqMan allelic discrimination assay to genotype three SNPs on an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). For quality control, two blank controls were set in each 384-well plate, and a 100% concordance was achieved in 10% random samples. The success rates of genotyping for selected SNPs were all above 95%. The samples failed for genotyping were excluded from the statistical analyses. The genotyping results were read by SDS 2.3 software (Applied Biosystems, Foster City, CA, USA). The primers and probes sequences for those SNPs were listed in Additional file 1: Table S1.

Relevant public database

The genotype information of TNFRSF5 in CHB population was downloaded from the 1000 Genomes Project Phase3 SNP database (www.​internationalgen​ome.​org). We have attempted to find expression quantitative trait loci (eQTL) evidence of positive loci based on the public GTEx Portal V6p database (http://​www.​gtexportal.​org/​). SNP functional annotations were performed on the HaploReg v4.1 database (http://​archive.​broadinstitute.​org/​mammals/​haploreg/​haploreg.​php), SNP Function Prediction (https://​snpinfo.​niehs.​nih.​gov/​snpinfo/​snpfunc.​html) and UCSC genome browser (https://​genome.​ucsc.​edu/​cgi-bin/​hgGateway).

Statistical analysis

For further susceptibility analysis, Group B and Group C were combined as HCV infected group, then compared with Group A which are health subjects. For HCV chronicity analysis, Group C was contrasted with Group B. Differences of the distribution in demographic and clinical characteristics were compared between subjects among three groups. Wherever appropriate, these differences were evaluated using Student’s t test, χ2-test, Kruskal–Wallis test or one-way analysis of variance. A goodness of fit χ2 test was used to test Hardy–Weinberg equilibrium (HWE) for each SNP among healthy subjects. Linkage disequilibrium (LD) parameters (r2 and D′) of selected SNPs in CHB population were estimated by Haploview software (version 4.2). The odds ratios and 95% confidence intervals were used to estimate the association between SNPs and the HCV infection outcomes by adjusting age, gender and routes of infection using both univariate and multivariate logistic regression models in this cross-sectional study. P<0.05 in a two-sided test was considered statistically significant. Bonferroni correction was used to conduct multiple comparisons among genotypes and the P value was adjusted to 0.0167 (0.05/3). All the analyses were carried out by Stata/SE (V.12.0 for Windows; StataCorp LP, College Station, TX, USA).

Results

General demographic information

Demographical and clinical characteristics of all subjects were listed in Table 1. The distribution of age and gender were balanced among Group A, Group B and Group C (all P > 0.05), while the ALT, AST and routes of infection were significantly different among three groups (all P < 0.001). HCV genotypes of partial HCV patients were statistically different between Group B and Group C (P<0.05). The three SNPs were all in accordance with Hardy-Weinberg equilibrium in the Group A (P = 0.553 for rs1535045, P = 0.130 for rs1883832 and P = 0.723 for rs4810485).
Table 1
Demographical and clinical characteristics among HCV control, spontaneous clearance and persistent infection populations
Variables
Group A (%)
Group B (%)
Group C (%)
P
n = 1513
n = 496
n = 768
Age (years, mean ± SD)
52.65 ± 13.30
51.12 ± 13.82
51.89 ± 12.37
0.076a
Gender
   
0.130b
 Male
603 (39.9)
194 (39.1)
273 (35.5)
 
 Female
910 (60.1)
302 (60.9)
495 (65.5)
 
ALT (U/L)
   
< 0.001b
 < 40
1421 (94.9)
387 (78.2)
443 (57.8)
 
 ≥40
77 (5.1)
108 (21.8)
323 (42.2)
 
AST (U/L)
    
 < 40
1422 (95.1)
394 (80.9)
454 (60.0)
< 0.001b
 ≥40
74 (4.9)
93 (19.1)
303 (40.0)
 
Route of infection
   
< 0.001b
 HD
553 (36.5)
91 (18.3)
76 (9.9)
 
 IVDU
181 (12.0)
138 (27.8)
140 (18.2)
 
 PBD
779 (51.5)
267 (53.9)
552 (71.9)
 
HCV genotypes
   
< 0.001b
 1b
42 (26.3)
223 (46.1)
 
 Non-1b
118 (73.7)
261 (53.9)
 
Abbreviations: ALT alanine transaminase, AST aspartate aminotransferase, HCV hepatitis C virus, HD hemodialysis, IVDU Intravenous drug user, PBD paid blood donors
Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients
a P value of one-way ANOVA among three groups
b P value of χ2-test among three/two groups

Association between polymorphisms in CD40 gene and susceptibility to HCV infection

The distributions of rs1535045, rs1883832, and rs4810485 genotypes among Group A, Group B, and Group C were shown in Table 2. To explore the association between CD40 polymorphisms and hepatitis C susceptibility, logistic regression methods were used by constructing three genetic models (additive, dominant and recessive). After adjusted by age, gender and routes of infection, the logistic regression analysis discovered that rs1535045 T allele was remarkably bound up with higher risk to infect HCV compared with C allele (in recessive model, adjusted OR = 1.368, 95%CI = 1.070-1.749, P = 0.012). Subjects carried rs1535045 TT genotype were more likely to infect HCV than wild CC genotype (adjusted OR = 1.397, 95%CI = 1.078-1.809, P = 0.011). For rs1883832, T allele was significantly associated with an increased risk of HCV infection (in recessive model, adjusted OR = 1.337, 95%CI = 1.069-1.673, P = 0.011). Subjects with TT genotype had higher possibility to infect HCV (adjusted OR = 1.351, 95%CI = 1.060-1.702, P = 0.015).
Table 2
Genotypes distributions of TNFRSF5 SNPs among control, spontaneous clearance and persistent infection groups
SNPs (genotype)
Group A
Group B
Group C
Group (B + C)/Group A
Group C/Group B
n(%)
n(%)
n(%)
OR(95%CI)a
P a
OR(95%CI)b
P b
rs1535045
 CC
688 (46.5)
214 (43.9)
328 (43.6)
1.00
1.00
 CT
648 (43.8)
211 (43.3)
322 (42.8)
1.043 (0.884-1.231)
0.618
0.979 (0.763-1.256)
0.867
 TT
142 (9.7)
62 (12.8)
103 (13.6)
1.397 (1.078-1.809)
0.011
1.095 (0.760-1.576)
0.626
Dominant model
   
1.109 (0.948-1.297)
0.197
1.005 (0.796-1.271)
0.964
Additive model
   
1.135 (1.011-1.275)
0.032
1.027 (0.869-1.215)
0.752
Recessive model
   
1.368 (1.070-1.749)
0.012
1.106 (0.785-1.559)
0.564
rs1883832
 CC
567 (39.4)
178 (37.3)
275 (37.7)
1.00
1.00
 CT
693 (48.2)
217 (45.5)
333 (45.6)
1.019 (0.858-1.210)
0.833
1.008 (0.778-1.306)
0.951
 TT
178 (12.4)
82 (17.2)
122 (16.7)
1.351 (1.060-1.722)
0.015
0.980 (0.695-1.383)
0.909
Dominant model
   
1.090 (0.926-1.282)
0.300
1.001 (0.785-1.275)
0.997
Additive model
   
1.127 (1.004-1.263)
0.042
0.993 (0.841-1.173)
0.937
Recessive model
   
1.337 (1.069-1.673)
0.011
0.976 (0.713-1.335)
0.878
rs4810485
 GG
604 (40.6)
190 (39.7)
306 (41.0)
1.00
1.00
 GT
693 (46.6)
211 (44.1)
328 (43.9)
0.970 (0.819-1.148)
0.721
0.981 (0.761-1.266)
0.885
 TT
191 (12.8)
78 (16.2)
113 (15.1)
1.201 (0.944-1.527)
0.136
0.927 (0.655-1.312)
0.667
Dominant model
   
1.021 (0.871-1.196)
0.802
0.967 (0.762-1.227)
0.780
Additive model
   
1.063 (0.949-1.190)
0.290
0.967 (0.819-1.141)
0.688
Recessive model
   
1.220 (0.976-1.526)
0.081
0.936 (0.679-1.290)
0.685
Abbreviations: CI confidence interval, HCV hepatitis C virus, OR odds ratio, SNP single nucleotide polymorphism
Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients. Group (B + C): Infected individuals
aThe P value, OR and 95% CIs of Group (B + C) versus Group A were calculated on the basis of the logistic regression model, adjusted by gender, age and routes of infection
bThe P value, OR and 95% CIs of Group C versus Group B were calculated on the basis of the logistic regression model, adjusted by gender, age and routes of infection
Bonferroni correction was applied and the P value was adjusted to 0.0167 (0.05/3)
Bold type indicates statistically significant results

Association of CD40 polymorphisms with the spontaneous clearance of HCV infection

When exploring the association of TNRSF5 polymorphisms with the spontaneous clearance of HCV infection, we proceeded association study by comparing the distribution of genotypes of selected SNPs in the persistent infection group and spontaneous clearance group after the adjustment by gender, age and routes of infection. No significant association was discovered in any of the three SNPs (rs1535045, rs1883832 and rs4810485) with the virus spontaneous clearance both in the additive, dominant, recessive models (all P>0.05, Table 2).

Stratified analysis

Considering that the genetic pattern of positive SNPs is recessive, we conducted the stratification analysis in recessive model (Table 3). We found that the rs1535045 were significant in female (adjusted OR = 1.639, 95%CI = 1.181-1.274, P = 0.003) and paid blood donors (adjusted OR = 1.417, 95%CI = 1.013-1.985, P = 0.042) subgroups after adjusted by age, gender and routes of infection. As for rs1883832, it remained meaningful in young (adjusted OR = 1.485, 95%CI = 1.020-2.162, P = 0.039), male (adjusted OR = 1.532, 95%CI = 1.077-2.180, P = 0.018), hemodialysis patients (adjusted OR = 2.042, 95%CI = 1.225-3.404, P = 0.006) and paid blood donors (adjusted OR = 1.836, 95%CI = 1.021-3.304, P = 0.043) subgroups. The heterogeneity test showed no pronounced heterogeneity in any pairwise comparison (P > 0.05).
Table 3
Stratified analysis of rs1535045 and rs1883832 among control, spontaneous clearance and persistent infection groups
SNPs
Allele
Subgroups
Group (B + C)/Group A
OR(95%CI)a
P a
P b
rs1535045
C/T
Age
<50
1.417 (0.973-2.064)
0.069
0.787
≥50
1.323 (0.955-1.832)
0.092
Gender
male
1.240 (0.764-1.652)
0.551
0.158
female
1.639 (1.181-1.274)
0.003
Routes of infection
HD
1.285 (0.684-2.413)
0.436
0.479
Drug user
0.985 (0.607-1.598)
0.951
PBD
1.418 (1.013-1.985)
0.042
rs1883832
C/T
Age
<50
1.485 (1.020-2.162)
0.039
0.572
≥50
1.297 (0.979-1.719)
0.070
Gender
male
1.532 (1.077-2.180)
0.018
0.344
female
1.228 (0.917-1.646)
0.168
Routes of infection
HD
2.042 (1.225-3.404)
0.006
0.066
Drug user
1.836 (1.021-3.304)
0.043
PBD
1.111 (0.839 -1.471)
0.168
Abbreviations: CI confidence interval, HD hemodialysis, PBD paid blood donors, OR odds ratio
Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients. Group (B + C): HCV-infected individuals
a The P value, OR and 95% CIs of group (B + C) versus Group A were calculated on the basis of the binary logistic regression model, adjusted by gender, age and routes of infection in recessive model (TT versus [TC + CC])
b The P value for the heterogeneity test
Bold type indicates statistically significant results

Cumulative effects of rs1535045 and rs1883832 on the susceptibility of HCV infection

The analysis of combined risk alleles (rs1535045 T allele and rs1883832 T allele) came to conclusions that subjects carried three risk alleles or four risk alleles were more likely to be infected when compared with subjects carried no risk alleles (adjusted OR = 1.947, 95%CI = 1.741-2.179, P<0.001, Table 4). Nevertheless, those carried one and two risk alleles showed no higher possibility to infect HCV than subjects who carried risk-free alleles. These two SNPs had trend influence on more possibility of being infected by HCV after the Cochran–Armitage trend test (P<0.001).
Table 4
Cumulative effects of combined risk alleles (rs1535045 T and rs1883832 T) on the susceptibility to HCV infection
Variables
Group A
Group B+ Group C
Group (B + C)/Group A
n
n
OR(95%CI)a
P a
0
154
123
1
 
1
619
444
0.965 (0.734-1.269)
0.799
2
615
550
1.179 (0.899-1.546)
0.233
3 4
29
64
1.947 (1.741-2.179)
<0.001
Trend
   
<0.001 b
0
154
123
1
 
1-4
1362
1138
1.114 (0.862-1.440)
0.411
Abbreviations: HCV hepatitis C virus, OR odds ratio,95% CI 95% confidence interval
Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients. Group (B + C): HCV-infected individuals
aLogistic regression model, adjusted for gender, age, and routes of infection
bCochran–Armitage trend test
Bold type indicates statistically significant results

Haplotype analysis

According to the information from Haploview software (version 4.2), the rs1535045 (C/T) and rs1883832 (C/T) were strongly linkage disequilibrium (D’ = 1.000, r2 = 0.283). As these two SNPs were both associated with increased risk of HCV infection, we evaluated the combined effects of these two SNPs on HCV susceptibility by haplotype analysis. As shown in Table 5, compared with most frequent CC haplotype, subjects carrying haplotype CT (adjusted OR = 1.161, 95%CI = 1.015-1.327, P = 0.029), TC (adjusted OR = 1.151, 95%CI = 1.002-1.323, P = 0.047) and TT (adjusted OR = 2.550, 95%CI = 1.665-3.905, P<0.001) were more likely to infect HCV.
Table 5
Haplotype analysis of rs1535045 and rs1883832 in the study population
Variables
Group A
Group B+ Group C
Group (B + C)/Group A
n
n
OR(95%CI)a
P a
CC
985
728
1
 
CT
1087
929
1.161 (1.015-1.327)
0.029
TC
927
789
1.151 (1.002-1.323)
0.047
TT
33
76
2.550 (1.665-3.905)
<0.001
Abbreviations: HCV hepatitis C virus, OR odds ratio, 95% CI 95% confidence interval
Group A: controls; Group B: spontaneous clearance subjects; Group C: persistent infection patients. Group (B + C): HCV-infected individuals
aLogistic regression model, adjusted for gender, age and routes of infection
Bold type indicates statistically significant results

Discussion

Up to now, the pathogenesis of HCV has not been illuminated clearly enough because a number of immune-related pathways and a series of genes involve in the process of HCV infection. Growing researches on HCV are paid attention to find more genetic variations in order to identify relevant biological markers of the disease. We explored the possible associations between three CD40 SNPs (rs1535045, rs1883832 and rs4810485) and HCV infection outcomes. In this study, we found that genetic variants of CD40 (rs1535045 T allele and rs1883832 T allele) were significantly associated with an increased risk of HCV infection among Chinese population at the fist time.
TNFRSF5 encodes a costimulatory protein called CD40, which have been found on antigen presenting cells. The CD40 has been found to play an essential role in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation [7, 15]. Various cytokines can control the expression level of CD40, particularly the IFN-γ, IL-1β, and TNF-α enhancing the expression on monocytes [16], endothelial cells [17, 18], thymic epithelium [19] and in six HCC cell lines [20]. In HCV-associated chronic liver diseases, CD40 might have important effects on hepatocyte survival and death in HCV-associated chronic liver diseases [8]. Studies demonstrated that CD40 signal can activate NF-κB in a dose-dependent manner, then NF-κB inhibits Fas or Tumor Necrosis Factor Receptor (TNFR) mediated apoptosis by blocking the activation of caspase-8 [21, 22]. Specifically, CD40 is up-regulated on hepatocytes during infection with hepatitis C virus, can inhibit HCV replication and mediate viral clearance, and disruptions by activated innate immune mechanism [9].
In our study, we found rs1535045 (located in intron1 of TNFRSF5) and rs1883832 (located in 5’UTR of TNFRSF5) have an association with susceptibility to HCV infection. However, no significant association was found among the three candidate SNPs and the spontaneous clearance of HCV, which may be related to the smaller sample size included in the analysis. Therefore, this result should be further verified in large sample studies. These SNPs had been broadly researched in different genetic backgrounds. It turned out that rs1535045 had connection to many diseases, such as coronary artery calcification [23] and small cell lung cancer [11], and rs1883832 was related to systemic lupus erythematosus [24] and acute coronary syndrome [25].
According to the bioinformatics information from UCSC, SNP rs1535045 was situated in highest peak of the H3k4me1, H3k4me3 and H3k27AC histone marker in 7 cell lines which were potential regulatory elements region (Fig. 1). We found rs1883832 was located at peak of transcription level assayed by RNA-seq on 9 cell lines from ENCODE and H3k27AC histone marker in 7 cell lines (Fig. 1). Recent studies have found that probable pathogenic SNPs are enriched in the enhancer region and regulatory elements region, particularly in the H3K27Ac region, indicating that these mutations may have possible functions on gene transcription and expression process and then effect the disease susceptibility and outcomes [26, 27]. Besides, we identified whether these SNP could cause any differential expression of mRNA in different tissues by eQTL analysis. It turned out that different genotypes of rs1883832 could cause differential mRNA level of CD40 in whole blood (P = 2.7 × 10− 9) (Fig. 2). Subjects carried the risk TT genotype had a lower CD40 mRNA levels, it was consistent with the results found by Rau SJ et al. that CD40 could inhibit HCV replication and mediate viral clearance, and disruptions [9].
In the stratified analysis, considering that the genetic pattern of positive SNPs is recessive, we conducted the analysis in recessive model. We found that rs1535045 and rs1883832 significantly increased the risk of HCV infection in some subgroups. Although different gender and route of infection can bring complex infection environment and immune response, rs1535045 T allele and rs1883832 T allele remained meaningful in various subgroups. In addition, the results of the cumulative effects and haplotype analyses showed a tendency of that the more risk alleles (rs1535045 T and rs1883832 T) subjects carried, the more possibility of HCV infection exhibited.
This research did have some limitations. First of all, the samples included in this study were poorly representative and lacked important information that might affect the outcome, such as HCV genotype and IL28B genotyping results. Second, this is a cross-sectional study and the association should be better verified in cohort study. Third, the evidence based on bioinformatics analysis was obtained on the computer simulation, further functional experiment should be carried out. In addition, this study only included high-risk populations of HCV infection, which may overestimate the association between candidate SNPs and the susceptibility of HCV infection. Therefore, our results must be verified in larger cohorts in the future.

Conclusion

CD40 polymorphisms was significantly associated with the susceptibility to HCV among Chinese populations. Further functional studies are needed to confirm the biological significance of these positive SNPs. This study provided the genetic evidence of association between CD40 polymorphisms and the outcome of HCV infection, and they may lead other scientists and clinician to identify new targets for therapy and personalized medical-based strategy by combined with other molecular genetics information.

Supplementary information

Supplementary information accompanies this paper at https://​doi.​org/​10.​1186/​s12879-019-4482-5.

Acknowledgements

The authors wish to thank Jie Wang, Yan Wang and Xiangyu Ye, for all the contributions to make this study carried out.
This study was given permission by the medical ethics committee of Nanjing Medical University. All subjects had signed agreements on the informed consent materials to participate in this study.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14(2):122–32.CrossRef Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14(2):122–32.CrossRef
2.
Zurück zum Zitat Shoukry NH, Hepatitis C. Vaccines, antibodies, and T cells. Front Immunol. 2018;9:1480.CrossRef Shoukry NH, Hepatitis C. Vaccines, antibodies, and T cells. Front Immunol. 2018;9:1480.CrossRef
3.
Zurück zum Zitat Horner SM, Gale M. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med. 2013;19(7):879–88.CrossRef Horner SM, Gale M. Regulation of hepatic innate immunity by hepatitis C virus. Nat Med. 2013;19(7):879–88.CrossRef
4.
Zurück zum Zitat Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, Kim AY, Lauer GM, Chung RT, Peters MG, Kirk GD, Mehta SH, Cox AL, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Tobler LH, Busch MP, Alexander G, Rosen HR, Gao X, Abdel-Hamid M, Apps R, Carrington M, Thomas DL. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med. 2013;158:235–45.CrossRef Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, Kim AY, Lauer GM, Chung RT, Peters MG, Kirk GD, Mehta SH, Cox AL, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Tobler LH, Busch MP, Alexander G, Rosen HR, Gao X, Abdel-Hamid M, Apps R, Carrington M, Thomas DL. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med. 2013;158:235–45.CrossRef
5.
Zurück zum Zitat Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.CrossRef Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.CrossRef
6.
Zurück zum Zitat Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.CrossRef Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.CrossRef
7.
Zurück zum Zitat Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC. Mechanism of antigen-driven selection in germinal centres. Nature. 1989;342(6252):929–31.CrossRef Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC. Mechanism of antigen-driven selection in germinal centres. Nature. 1989;342(6252):929–31.CrossRef
8.
Zurück zum Zitat Shiraki K, Sugimoto K, Okano H, Wagayama H, Fujikawa K, Yamanaka T, Ito T, Ohmori S, Sakai T, Takase K, Nakano T. CD40 expression in HCV-associated chronic liver diseases. Int J Mol Med. 2006;18(4):559–63.PubMed Shiraki K, Sugimoto K, Okano H, Wagayama H, Fujikawa K, Yamanaka T, Ito T, Ohmori S, Sakai T, Takase K, Nakano T. CD40 expression in HCV-associated chronic liver diseases. Int J Mol Med. 2006;18(4):559–63.PubMed
9.
Zurück zum Zitat Rau SJ, Hildt E, Himmelsbach K, Thimme R, Wakita T, Blum HE, Fischer R. CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c-Jun N terminal kinase activation independent from the interferon pathway. Hepatology. 2013;57(1):23–36.CrossRef Rau SJ, Hildt E, Himmelsbach K, Thimme R, Wakita T, Blum HE, Fischer R. CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c-Jun N terminal kinase activation independent from the interferon pathway. Hepatology. 2013;57(1):23–36.CrossRef
10.
Zurück zum Zitat Chen JM, Guo J, Wei CD, Wang CF, Luo HC, Wei YS, Lan Y. The association of CD40 polymorphisms with CD40 serum levels and risk of systemic lupus erythematosus. BMC Genet. 2015;16:121.CrossRef Chen JM, Guo J, Wei CD, Wang CF, Luo HC, Wei YS, Lan Y. The association of CD40 polymorphisms with CD40 serum levels and risk of systemic lupus erythematosus. BMC Genet. 2015;16:121.CrossRef
11.
Zurück zum Zitat Tang W, Xue L, Yan Q, Cai S, Bai Y, Lin L, Lin B, Huang M, Yi G, Li H. Association of Single Nucleotide Polymorphisms in the apoptosis-related genes TP63 and CD40 with risk for lung Cancer in a Chinese Han population. Tohoku J Exp Med. 2016;238(4):279–86.CrossRef Tang W, Xue L, Yan Q, Cai S, Bai Y, Lin L, Lin B, Huang M, Yi G, Li H. Association of Single Nucleotide Polymorphisms in the apoptosis-related genes TP63 and CD40 with risk for lung Cancer in a Chinese Han population. Tohoku J Exp Med. 2016;238(4):279–86.CrossRef
12.
Zurück zum Zitat Zhou L, Xie L, Zheng D, Li N, Zhu J, Wang S, Li B, Ye L. Genetic variants of CD40 gene are associated with coronary artery disease and blood lipid levels. Biomed Res Int. 2016;2016:1693619.PubMedPubMedCentral Zhou L, Xie L, Zheng D, Li N, Zhu J, Wang S, Li B, Ye L. Genetic variants of CD40 gene are associated with coronary artery disease and blood lipid levels. Biomed Res Int. 2016;2016:1693619.PubMedPubMedCentral
13.
Zurück zum Zitat Liu ZL, Hu J, Xiao XF, Peng Y, Zhao SP, Xiao XZ, Yang MS. The CD40 rs1883832 polymorphism affects Sepsis susceptibility and sCD40L levels. Biomed Res Int. 2018;2018:7497314.PubMedPubMedCentral Liu ZL, Hu J, Xiao XF, Peng Y, Zhao SP, Xiao XZ, Yang MS. The CD40 rs1883832 polymorphism affects Sepsis susceptibility and sCD40L levels. Biomed Res Int. 2018;2018:7497314.PubMedPubMedCentral
14.
Zurück zum Zitat Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. Associations between the functional CD40 rs4810485 G/T polymorphism and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Lupus. 2015;24:1177–83.CrossRef Lee YH, Bae SC, Choi SJ, Ji JD, Song GG. Associations between the functional CD40 rs4810485 G/T polymorphism and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Lupus. 2015;24:1177–83.CrossRef
15.
Zurück zum Zitat Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111–35.CrossRef Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111–35.CrossRef
16.
Zurück zum Zitat Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med. 1993;178(2):669–74.CrossRef Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med. 1993;178(2):669–74.CrossRef
17.
Zurück zum Zitat Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci U S A. 1995;92(10):4342–6.CrossRef Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci U S A. 1995;92(10):4342–6.CrossRef
18.
Zurück zum Zitat Kluth B, Hess S, Engelmann H, Schafnitzel S, Riethmüller G, Feucht HE. Endothelial expression of CD40 in renal cell carcinoma. Cancer Res. 1997;57(5):891–9.PubMed Kluth B, Hess S, Engelmann H, Schafnitzel S, Riethmüller G, Feucht HE. Endothelial expression of CD40 in renal cell carcinoma. Cancer Res. 1997;57(5):891–9.PubMed
19.
Zurück zum Zitat Galy AH, Spits H. CD40 is functionally expressed on human thymic epithelial cells. J Immunol. 1992;149(3):775–82.PubMed Galy AH, Spits H. CD40 is functionally expressed on human thymic epithelial cells. J Immunol. 1992;149(3):775–82.PubMed
20.
Zurück zum Zitat Sugimoto K, Shiraki K, Ito T, Fujikawa K, Takase K, Tameda Y, Moriyama M, Nakano T. Expression of functional CD40 in human hepatocellular carcinoma. Hepatology. 1999;30(4):920–6.CrossRef Sugimoto K, Shiraki K, Ito T, Fujikawa K, Takase K, Tameda Y, Moriyama M, Nakano T. Expression of functional CD40 in human hepatocellular carcinoma. Hepatology. 1999;30(4):920–6.CrossRef
21.
Zurück zum Zitat Hayden MS, Ghosh S. Regulation of NF-κB by TNF family cytokines. Semin Immunol. 2014;26(3):253–66.CrossRef Hayden MS, Ghosh S. Regulation of NF-κB by TNF family cytokines. Semin Immunol. 2014;26(3):253–66.CrossRef
22.
Zurück zum Zitat Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281(5383):1680–3.CrossRef Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281(5383):1680–3.CrossRef
23.
Zurück zum Zitat Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Carr JJ, Rich SS, Freedman BI, Herrington D, Bowden DW. Variants of the CD40 gene but not of the CD40L gene are associated with coronary artery calcification in the diabetes heart study (DHS). Am Heart J. 2006;151(3):706–11.CrossRef Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Carr JJ, Rich SS, Freedman BI, Herrington D, Bowden DW. Variants of the CD40 gene but not of the CD40L gene are associated with coronary artery calcification in the diabetes heart study (DHS). Am Heart J. 2006;151(3):706–11.CrossRef
24.
Zurück zum Zitat Joo YB, Park BL, Shin HD, Park SY, Kim I, Bae SC. Association of genetic polymorphisms in CD40 with susceptibility to SLE in the Korean population. Rheumatology (Oxford). 2013;52(4):623–30.CrossRef Joo YB, Park BL, Shin HD, Park SY, Kim I, Bae SC. Association of genetic polymorphisms in CD40 with susceptibility to SLE in the Korean population. Rheumatology (Oxford). 2013;52(4):623–30.CrossRef
25.
Zurück zum Zitat Wang M, Li Y, Li W, Xia ZE, Wu Q. The CD40 gene polymorphism rs1883832 is associated with risk of acute coronary syndrome in a Chinese case-control study. DNA Cell Biol. 2011;30(3):173–8.CrossRef Wang M, Li Y, Li W, Xia ZE, Wu Q. The CD40 gene polymorphism rs1883832 is associated with risk of acute coronary syndrome in a Chinese case-control study. DNA Cell Biol. 2011;30(3):173–8.CrossRef
26.
Zurück zum Zitat Farh KK, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, Shoresh N, Whitton H, Ryan RJ, Shishkin AA, Hatan M, Carrasco-Alfonso MJ, Mayer D, Luckey CJ, Patsopoulos NA, De Jager PL, Kuchroo VK, Epstein CB, Daly MJ, Hafler DA, Bernstein BE. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2015;518(7539):337–43.CrossRef Farh KK, Marson A, Zhu J, Kleinewietfeld M, Housley WJ, Beik S, Shoresh N, Whitton H, Ryan RJ, Shishkin AA, Hatan M, Carrasco-Alfonso MJ, Mayer D, Luckey CJ, Patsopoulos NA, De Jager PL, Kuchroo VK, Epstein CB, Daly MJ, Hafler DA, Bernstein BE. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature. 2015;518(7539):337–43.CrossRef
27.
Zurück zum Zitat Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4):934–47.CrossRef Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4):934–47.CrossRef
Metadaten
Titel
CD40 polymorphisms were associated with HCV infection susceptibility among Chinese population
verfasst von
Ting Tian
Peng Huang
Jingjing Wu
Chunhui Wang
Haozhi Fan
Yun Zhang
Rongbin Yu
Chao Wu
Xueshan Xia
Zuqiang Fu
Jun Li
Ming Yue
Publikationsdatum
01.12.2019
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2019
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-4482-5

Weitere Artikel der Ausgabe 1/2019

BMC Infectious Diseases 1/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.